Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach Antonio Garcia Molina

Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients A. Garcia-Molina, Alos-Alminana

Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophil-cytoplasm antibody associated vasculitides Ana Belén Guisado-Gil, Marina Muñoz-Burgos, Ana Ortega-Eslava, Francisco Javier García-Hernández, Bernardo Santos-Ramos